{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:31:09Z","timestamp":1773289869140,"version":"3.50.1"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:sec><jats:title>Learning Objectives<\/jats:title><jats:p>After completing this course, the reader will be able to: Describe the role played by EGF and EGFR in lung carcinogenesis.Discuss how different polymorphic alleles from the EGF and EGFR genes may affect drug response.Evaluate the value of determining the presence of EGF and EGFR polymorphisms in NSCLC patients for daily clinical practice.<\/jats:p><jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.12-2-201","type":"journal-article","created":{"date-parts":[[2007,2,12]],"date-time":"2007-02-12T19:44:08Z","timestamp":1171309448000},"page":"201-210","source":"Crossref","is-referenced-by-count":64,"title":["Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer\u2014A Review of the Literature"],"prefix":"10.1093","volume":"12","author":[{"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"first","affiliation":[{"name":"a Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"},{"name":"b ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal"},{"name":"c Molecular Oncology\u2014CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Ricardo","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"b ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal"},{"name":"c Molecular Oncology\u2014CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Isabel","family":"Azevedo","sequence":"additional","affiliation":[{"name":"a Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Ana","family":"Coelho","sequence":"additional","affiliation":[{"name":"c Molecular Oncology\u2014CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Marta","family":"Soares","sequence":"additional","affiliation":[{"name":"a Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Berta","family":"Sousa","sequence":"additional","affiliation":[{"name":"a Department of Medical Oncology, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Daniela","family":"Pinto","sequence":"additional","affiliation":[{"name":"c Molecular Oncology\u2014CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[{"name":"b ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal"},{"name":"c Molecular Oncology\u2014CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"b ICBAS, Abel Salazar Institute for Biomedical Sciences, University of Porto, Porto, Portugal"},{"name":"c Molecular Oncology\u2014CI, Portuguese Institute of Oncology, Porto Centre, Porto, Portugal"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[{"name":"d Department of Clinical and Biological Sciences, University of Torino, Torino, Italy"}]}],"member":"286","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"2021122208300319100_R1","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.2005.10.462","article-title":"Epidemiology of lung cancer: Looking to the future","volume":"23","author":"Alberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.04.8678","article-title":"Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening\u2014a report from the American Society of Clinical Oncology","volume":"24","author":"Herbst","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<870::AID-IJC35>3.0.CO;2-9","article-title":"Estimates of the worldwide mortality from 25 cancers in 1990","volume":"83","author":"Pisani","year":"1999","journal-title":"Int J Cancer"},{"key":"2021122208300319100_R4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/tc.3.3.242","article-title":"A descriptive model of the cigarette epidemic in developed countries","volume":"3","author":"Lopez","year":"1994","journal-title":"Tobacco Control"},{"key":"2021122208300319100_R5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1056\/NEJMra035536","article-title":"Multidisciplinary management of lung cancer","volume":"350","author":"Spira","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122208300319100_R6","doi-asserted-by":"crossref","first-page":"242s","DOI":"10.1378\/chest.112.4_Supplement.242S","article-title":"Implications of staging in lung cancer","volume":"112","author":"Naruke","year":"1997","journal-title":"Chest"},{"key":"2021122208300319100_R7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"1995","journal-title":"BMJ"},{"key":"2021122208300319100_R8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/313745a0","article-title":"Autocrine growth factors and cancer","volume":"313","author":"Sporn","year":"1985","journal-title":"Nature"},{"key":"2021122208300319100_R9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1659742","article-title":"Growth factors and cancer","volume":"254","author":"Aaronson","year":"1991","journal-title":"Science"},{"key":"2021122208300319100_R10","first-page":"1015","article-title":"Growth factors and cancer","volume":"46","author":"Goustin","year":"1986","journal-title":"Cancer Res"},{"key":"2021122208300319100_R11","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/annonc\/mdi355","article-title":"Novel targeted therapies in the treatment of gastric and esophageal cancer","volume":"16","author":"Tabernero","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122208300319100_R12","doi-asserted-by":"crossref","first-page":"27595","DOI":"10.1016\/S0021-9258(18)47026-3","article-title":"Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells","volume":"269","author":"Fan","year":"1994","journal-title":"J Biol Chem"},{"key":"2021122208300319100_R13","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208300319100_R14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208300319100_R15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2144\/000112043","article-title":"Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development","volume":"39","author":"Yan","year":"2005","journal-title":"Biotechniques"},{"key":"2021122208300319100_R16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/35057149","article-title":"International SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms","volume":"409","author":"Sachidanandam","year":"2001","journal-title":"Nature"},{"key":"2021122208300319100_R17","first-page":"3433","article-title":"Outcome in prostate cancer: Association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7","volume":"8","author":"Medeiros","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122208300319100_R18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10147-003-0318-8","article-title":"Platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma: Glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome","volume":"8","author":"Medeiros","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"2021122208300319100_R19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pros.10348","article-title":"Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms","volume":"58","author":"Medeiros","year":"2004","journal-title":"Prostate"},{"key":"2021122208300319100_R20","first-page":"1","article-title":"CXCL12\u20133\u2032A polymorphism and lung cancer metastases protection: New perspectives in immunotherapy?","volume":"6","author":"Coelho","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"2021122208300319100_R21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"2021122208300319100_R22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2005.02.005","article-title":"Pharmacogenetics for individualized cancer chemotherapy","volume":"107","author":"Efferth","year":"2005","journal-title":"Pharmacol Ther"},{"key":"2021122208300319100_R23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ejca.2006.02.004","article-title":"A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer","volume":"42","author":"Ribeiro","year":"2006","journal-title":"Eur J Cancer"},{"key":"2021122208300319100_R24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2005.04.4420","article-title":"Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy","volume":"24","author":"Shepherd","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R25","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.77.7.4188","article-title":"Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor to chromosome 7","volume":"77","author":"Davies","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208300319100_R26","first-page":"375","article-title":"The human EGF receptor gene: Structure of the 110 kb locus and identification of sequences regulating its transcription","volume":"1","author":"Haley","year":"1987","journal-title":"Oncogene Res"},{"key":"2021122208300319100_R27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2021122208300319100_R28","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signalling network: Receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"2021122208300319100_R29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0014-4827(02)00101-5","article-title":"The deaf and the dumb: The biology of ErbB-2 and ErbB-3","volume":"284","author":"Citri","year":"2003","journal-title":"Exp Cell Res"},{"key":"2021122208300319100_R30","doi-asserted-by":"crossref","first-page":"4227s","DOI":"10.1158\/1078-0432.CCR-040007","article-title":"The biology of epidermal growth factor receptor in lung cancer","volume":"10","author":"Scagliotti","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208300319100_R31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2003.10.002","article-title":"Epidermal growth factor receptor: A promising target in solid tumours","volume":"30","author":"Laskin","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"2021122208300319100_R32","first-page":"2884","article-title":"Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas","volume":"5","author":"Akimoto","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122208300319100_R33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0360-3016(01)01609-1","article-title":"EGFR overexpression and radiation response in glioblastoma multiforme","volume":"51","author":"Barker","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122208300319100_R34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.0.CO;2-U","article-title":"Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck","volume":"5","author":"Sheridan","year":"1997","journal-title":"Radiat Oncol Investig"},{"key":"2021122208300319100_R35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/387512a0","article-title":"Neuregulin-2, a new ligand of ErbB3\/ErbB4-receptor tyrosine kinases","volume":"387","author":"Carraway","year":"1997","journal-title":"Nature"},{"key":"2021122208300319100_R36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/387509a0","article-title":"Ligands for ErbB-family receptors encoded by a neuregulin-like gene","volume":"387","author":"Chang","year":"1997","journal-title":"Nature"},{"key":"2021122208300319100_R37","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/sj.onc.1202631","article-title":"Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase","volume":"18","author":"Harari","year":"1999","journal-title":"Oncogene"},{"key":"2021122208300319100_R38","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1073\/pnas.94.18.9562","article-title":"Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4","volume":"94","author":"Zhang","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208300319100_R39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V","article-title":"Specificity within the EGF family\/ErbB receptor family signaling network","volume":"20","author":"Riese DJ","year":"1998","journal-title":"Bioessays"},{"key":"2021122208300319100_R40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","article-title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer","volume":"15","author":"Karunagaran","year":"1996","journal-title":"EMBO J"},{"key":"2021122208300319100_R41","doi-asserted-by":"crossref","first-page":"8865","DOI":"10.1074\/jbc.274.13.8865","article-title":"ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors","volume":"274","author":"Worthylake","year":"1999","journal-title":"J Biol Chem"},{"issue":"suppl 3","key":"2021122208300319100_R42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.8-suppl_3-5","article-title":"Signal events: Cell signal transduction and its inhibition in cancer","volume":"8","author":"Rowinsky","year":"2003","journal-title":"The Oncologist"},{"key":"2021122208300319100_R43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signalling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"2021122208300319100_R44","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R45","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R46","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122208300319100_R47","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"2021122208300319100_R48","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1200\/JCO.2005.01.0793","article-title":"Epidermal growth factor receptor gene mutations and increase copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer","volume":"23","author":"Takano","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R49","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1200\/JCO.2005.01.2823","article-title":"Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study","volume":"23","author":"Hirsch","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R50","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1200\/JCO.2005.97.008","article-title":"Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?","volume":"23","author":"Johnson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208300319100_R51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/hmg\/1.2.135","article-title":"Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro \u03b1 2 (I) collagen (COL1A2)","volume":"1","author":"Chi","year":"1992","journal-title":"Hum Mol Genet"},{"key":"2021122208300319100_R52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/dna.1997.16.443","article-title":"Competitive-differential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes","volume":"16","author":"Roetger","year":"1997","journal-title":"DNA Cell Biol"},{"key":"2021122208300319100_R53","first-page":"929","article-title":"Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations\u2014a link between genetics and epigenetics","volume":"15","author":"Gebhardt","year":"2000","journal-title":"Histol Histopathol"},{"key":"2021122208300319100_R54","doi-asserted-by":"crossref","first-page":"13176","DOI":"10.1074\/jbc.274.19.13176","article-title":"Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1","volume":"274","author":"Gebhardt","year":"1999","journal-title":"J Biol Chem"},{"key":"2021122208300319100_R55","first-page":"854","article-title":"Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression","volume":"60","author":"Buerger","year":"2000","journal-title":"Cancer Res"},{"key":"2021122208300319100_R56","first-page":"1009","article-title":"Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism","volume":"9","author":"Liu","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122208300319100_R57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.bi.56.070187.004313","article-title":"Receptors for epidermal growth factor and other polypeptide mitogens","volume":"56","author":"Carpenter","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"2021122208300319100_R58","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1158\/0008-5472.CAN-04-1036","article-title":"An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors","volume":"64","author":"Amador","year":"2004","journal-title":"Cancer Res"},{"key":"2021122208300319100_R59","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01243894-200606000-00005","article-title":"EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer","volume":"1","author":"Dubey","year":"2006","journal-title":"J Thorac Oncol"},{"key":"2021122208300319100_R60","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM200010263431703","article-title":"A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer","volume":"343","author":"Keller","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122208300319100_R61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01243894-200606000-00001","article-title":"EGFR. A prognostic and\/or predictive marker?","volume":"1","author":"Hirsch","year":"2006","journal-title":"J Thorac Oncol"},{"key":"2021122208300319100_R62","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1073\/pnas.82.15.4920","article-title":"Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene","volume":"82","author":"Ishii","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208300319100_R63","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1016\/S0021-9258(18)60621-0","article-title":"Epidermal growth factor receptor gene promoter: Deletion analysis and identification of nuclear protein binding sites","volume":"263","author":"Johnson","year":"1988","journal-title":"J Biol Chem"},{"key":"2021122208300319100_R64","first-page":"457","article-title":"Deletion mapping of DNA regions required for SV40 early region promoter function in vivo","volume":"1","author":"Fromm","year":"1982","journal-title":"J Mol Appl Genet"},{"key":"2021122208300319100_R65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/319246a0","article-title":"Transcription factor Sp1 recognizes a DNA sequence in the mouse dihydrofolate reductase promoter","volume":"319","author":"Dynan","year":"1986","journal-title":"Nature"},{"key":"2021122208300319100_R66","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1128\/MCB.18.12.7147","article-title":"The promyelocytic leukaemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter","volume":"18","author":"Vallian","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2021122208300319100_R67","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1016\/S0021-9258(18)68790-3","article-title":"Epidermal growth factor (EGF) receptor gene transcription: Requirement for Sp1 and an EGF receptor-specific factor","volume":"263","author":"Kageyama","year":"1988","journal-title":"J Biol Chem"},{"key":"2021122208300319100_R68","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1016\/S0021-9258(18)82358-4","article-title":"T3 receptor suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via overlapping DNA-binding sites","volume":"268","author":"Xu","year":"1993","journal-title":"J Biol Chem"},{"key":"2021122208300319100_R69","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/sj.onc.1205211","article-title":"Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells","volume":"21","author":"Grinstein","year":"2002","journal-title":"Oncogene"},{"key":"2021122208300319100_R70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/0008-5472.46.65.1","article-title":"A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res"},{"key":"2021122208300319100_R71","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208300319100_R72","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ijc.20591","article-title":"Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer","volume":"113","author":"Lee","year":"2005","journal-title":"Int J Cancer"},{"key":"2021122208300319100_R73","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nm0604-577","article-title":"Selecting the right patient for tumor therapy","volume":"10","author":"Arteaga","year":"2004","journal-title":"Nat Med"},{"key":"2021122208300319100_R74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000217659","article-title":"The epidermal growth factor: A review of structural and functional relationships in the normal organism and in cancer cells","volume":"11","author":"Laurence","year":"1990","journal-title":"Tumor Biol"},{"key":"2021122208300319100_R75","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J Biol Chem"},{"key":"2021122208300319100_R76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122208300319100_R77","first-page":"8887","article-title":"Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2\/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo","volume":"61","author":"Moulder","year":"2001","journal-title":"Cancer Res"},{"key":"2021122208300319100_R78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0100001","article-title":"Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment","volume":"10","author":"Normanno","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"2021122208300319100_R79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signalling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"2021122208300319100_R80","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(02)07600-6","article-title":"Association between functional polymorphism in EGF gene and malignant melanoma","volume":"359","author":"Shahbazi","year":"2002","journal-title":"Lancet"},{"key":"2021122208300319100_R81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/bjc.1995.35","article-title":"Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979\u201386, and their subsequent validation","volume":"71","author":"Mackie","year":"1995","journal-title":"Br J Cancer"},{"key":"2021122208300319100_R82","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ijc.11448","article-title":"EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma","volume":"107","author":"McCarron","year":"2003","journal-title":"Int J Cancer"},{"key":"2021122208300319100_R83","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/0008-5472.CAN-03-3855","article-title":"EGF gene polymorphism and the risk of incident primary melanoma","volume":"64","author":"Amend","year":"2004","journal-title":"Cancer Res"},{"key":"2021122208300319100_R84","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.0022-202X.2004.23305.x","article-title":"EGF polymorphism and risk of melanocytic neoplasia","volume":"123","author":"James","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2021122208300319100_R85","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.0022-202X.2004.23304.x","article-title":"The relationship between the epidermal growth factor (EGF) 5\u2032UTR variant A61G, and melanoma\/nevus susceptibility","volume":"123","author":"Randerson-Moor","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2021122208300319100_R86","doi-asserted-by":"crossref","first-page":"xx","DOI":"10.1111\/j.0022-202X.2004.23308.x","article-title":"Epidermal growth factor gene polymorphism and development of cutaneous melanoma","volume":"123","author":"Howell","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2021122208300319100_R87","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/0008-5472.CAN-03-3137","article-title":"A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease","volume":"64","author":"Bhowmick","year":"2004","journal-title":"Cancer Res"},{"key":"2021122208300319100_R88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000084116","article-title":"A single nucleotide polymorphism in the 5\u2032 untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer","volume":"72","author":"Hamai","year":"2005","journal-title":"Pathobiology"},{"key":"2021122208300319100_R89","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1158\/1055-9965.EPI-05-0401","article-title":"No association between EGF gene polymorphism and gastric cancer","volume":"14","author":"Goto","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-2-201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-2-201","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/2\/201\/41834906\/oncolo_12_2_201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/2\/201\/41834906\/oncolo_12_2_201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T22:39:07Z","timestamp":1707604747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/2\/201\/6413969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":89,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,2,1]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-2-201","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,2,1]]},"published":{"date-parts":[[2007,2,1]]}}}